Liposomal MRI Contrast Agent for Endothelial Dysfunction Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MRI contrast agents for cardiovascular diagnostics face challenges such as low molecular weight leading to nonspecific tissue penetration, toxicity issues with nanoparticles, and instability of lipid aggregates in the circulatory system, limiting their effectiveness in detecting early changes in endothelial dysfunction.
Innovation Solution
A hydrophilic Gd-diethylenetriaminepentaacetate-bis(methylamide) contrast agent encapsulated within single-layer liposomes of specific size and composition, including phosphatidylcholine, cholesterol, and PEG-PE, which ensures long-lasting circulation and accumulation in pathologically changed vascular endothelium, enhancing diagnostic sensitivity for endothelial function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If low molecular weight hydrophilic complexes are used, then toxicity is reduced, but selectivity and pharmacokinetic parameters deteriorate
Solution Approach 1:
The patent encapsulates the hydrophilic gadolinium complex within liposomes, creating a nested structure where the contrast agent is protected inside a lipid bilayer carrier. This allows the low molecular weight complex to maintain its low toxicity profile while the liposome provides the necessary stability and targeted accumulation in vascular endothelium, resolving the contradiction between low toxicity and adequate selectivity.
Solution Approach 2:
The liposome acts as an intermediary carrier between the gadolinium complex and the target tissue. It protects the hydrophilic complex from premature clearance while facilitating its accumulation in pathologically changed vascular endothelium, thereby improving selectivity without increasing the inherent toxicity of the gadolinium complex.
2Measurement precision
If amphiphilic complexes are used, then affinity for lipid aggregates improves, but stability in circulatory system deteriorates
Solution Approach 1:
The patent modifies the liposome composition by incorporating specific lipid ratios (phosphatidylcholine, cholesterol, and PEG-PE) and controlling liposome size (50-200 nm). These parameter changes optimize both the affinity for vascular endothelium and the stability in circulation, resolving the contradiction between affinity and stability.
Solution Approach 2:
The patent creates a composite liposomal structure combining multiple lipid components (phosphatidylcholine, cholesterol, and PEG-PE) with the gadolinium complex. This composite approach provides both lipid aggregate affinity and circulatory stability, as each component contributes specific properties that together resolve the contradiction.
3Measurement precision
If nanoparticles are used, then diagnostic sensitivity improves, but toxicity issues arise
Solution Approach 1:
The patent uses liposomes as temporary carriers that can be easily cleared from the body after delivering the contrast agent to the target tissue. This approach maintains high diagnostic sensitivity through the liposomal enhancement of gadolinium accumulation in vascular endothelium while avoiding the long-term toxicity accumulation associated with persistent nanoparticles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described contrast agent allows for sensitive detection of early endothelial dysfunction and atherosclerotic changes, providing non-invasive assessment of endothelial permeability and function, outperforming existing methods by enabling earlier diagnosis compared to traditional liposomal agents.
Implementation Method 1
A hydrophilic Gd-diethylenetriaminepentaacetate-bis(methylamide) contrast agent encapsulated within single-layer liposomes
Implementation Method 2
allows for sensitive detection of early endothelial dysfunction and atherosclerotic changes, providing non-invasive assessment of endothelial permeability
Implementation Method 3
MRI contrast agent for non-invasive diagnostics of early changes occurring in the course of the development of endothelial dysfunction
Data Source
Figure 1~2
Figure 3A~4B
Figure 5A~6
AI summary
MRI contrast agent for use in the diagnosis of early changes in the endothelium of blood vessels